Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.66 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.55 |
| ▸ | WIZ | O95785 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482861 | 1.00 | CRBN (0.66) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL29158021 | 0.93 | CRBN (0.69) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL30903865 | 0.93 | CRBN (0.69) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL24207034 | 0.93 | CRBN (0.69) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL30903866 | 0.92 | CRBN (0.67) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL30822444 | 0.91 | CRBN (0.66) | CRBN | |
| SCHEMBL23704734 | 0.91 | CRBN (0.66) | CRBN | |
| SCHEMBL24778755 | 0.91 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL20046071 | 0.90 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL20211856 | 0.90 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| CN-118344348-A | Heterocyclic substituted quinazoline and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| CN-118126035-A | Cycloalkyl or heterocycle substituted benzo or pyridopyridazine, and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117820305-A | Heterocyclic substituted quinazoline and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4342892-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| CN-117229286-A | Aromatic compound, preparation method thereof and application thereof in preparation of estrogen receptor degradation agent | 海创药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023274390-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557933-A | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 276/4885IKZF2 2302/4885WIZ 1329/4885 |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | CRBN 642/4885IKZF2 1064/4885WIZ 497/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 298/4885IKZF2 2350/4885WIZ 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.